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THE aim of this study was to examine glycoconjugate
secretion  in  human  airways  with  and  without  an
epithelium.  Glycoconjugate  release  in  supernatants
derived from human airways in vitro was determined
using  an  ELISA  assay  with  an  anti-human  mucin
monoclonal  antibody  (MAb  3D3).  This  monoclonal
antibody reacted strongly with Leb antigen but also
recognized in vitro Lea and Ley determinents. In 11 of
the  34  different  lung  samples  (32%)  studied  the
glycoconjugate levels were below the threshhold of
detection for this assay. The mean basal secretion of
glycoconjugates in human airways in vitro was 100 ±
28 m g/g tissue (Period  I;  n = 23 different  lung sam-
ples). The amount of glycoconjugate measured in the
medium derived from human isolated bronchial ring
preparations  did  not  change  under  control  condi-
tions during the  course of  the  experimental proce-
dure (Period I; 128 ± 46 m g/g tissue and Period II; 159
± 48 m g/g tissue; n = 13 paired lung samples). In the
supernatants  of  airway  preparations  with an  intact
epithelium  the  amount  of  glycoconjugates  detected
was 90 ± 38 m g/g tissue (Period I; n = 12 different lung
samples) and removal of the epithelium did not alter
this basal glycoconjugate release (94 ± 60 m g/g tissue:
Period I, n = 8 different lung samples). The absence of
the  epithelial  layer  was  confirmed  by  histological
evaluation. Methacholine (100 m M) induced a 10- and
four-fold  increase  in  glycoconjugate  release  from
airways with and without an epithelium, respectively.
In contrast, in preparations with an epithelium, LTD4
(10 m M) and anti-IgE (dilution: 1/1000) did not cause
an increase of glycoconjugate release. The methacho-
line difference between airways with and without an
epithelium was not significantly different (P > 0.10).
However,  a  treatment  with  atropine  (100 m M)  pre-
vented  the  increase  of  glycoconjugate  release  in
preparations with an epithelium. These data derived
from a limited number of experiments suggest that
the epithelium may not regulate the basal or stimu-
lated release of glycoconjugates from isolated human
airways.
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Introduction
Early  studies1,2 showed  that  the  constituents  of
mucus  are  derived  from  goblet  cells  and  the  sub-
mucosal  glands.  Coles  and  coworkers3 using
14C-glucosamine,  measured  radiolabelled  glycopro-
tein in the tissue medium from airway preparations
and demonstrated that the epithelium did not con-
tribute  to  the  basal  secretion  in  dog  respiratory
tract.  However,  removal  of  the  epithelium  signifi-
cantly  decreased  the  secretion  of  sulphated  glyco-
protein2 suggesting that some secretory constituents
may originate from the goblet cells in the epithelial
layer.  In  contrast,  Sasaki  and  coworkers4 demon-
strated that in cat airways the epithelium modulated
the  secretory  activity  of  the  submucosal  glands.
Since  the  epithelium  decreased  the  methacholine
induced glandular secretion, these authors suggested
the  liberation  of  an  epithelium  inhibitory  factor
which  modulated  the  mucin  release.  In  contrast,
Sherman  and  coworkers5 using  methacholine  dem-
onstrated  a  significant  release  of  mucus  glycopro-
teins in the absence of the epithelium. These latter
results would suggest that  the epithelium does not
contribute  significantly  to  the  glycoproteins
secreted. While  some  of  these  differences  may  be
related  to  the  species  in  which  the  experiments
were performed, there is little information available
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secretory activity in human  airways.
While the principal constituents of mucus are the
mucins, a variety of proteins, glycoconjugates (serum
type glycoproteins and proteoglycans) and glycolipids
are also produced and secreted.6–8 In an attempt to
characterize  those factors which  constitute respira-
tory secretion, Saint George and coworkers9 showed
that a number of monoclonal antibodies reacted with
material  in  goblet  cells  and/or  submucosal  mucus
gland cells, data which have been confirmed by other
investigators.10 Recently,  Emery  and  coworkers11
have  prepared  an  anti-human  mucin  MAb  against
purified  human  respiratory  mucins. These  authors
indicated  that  this  anti-human  MAb  3D3  was  not
specific  for  respiratory  mucin  but  reacted,  in  fact,
strongly  with  the  Lewis  b  (Leb)  antigen,  but  also
recognized Lea and Ley determinents using synthetic
oligosaccharides.  These  investigators  also  demon-
strated that in human airways the MAb 3D3 stained
goblet  cells  and  mucous  cells  of  the  submucosal
glands as well as human epithelial cells in culture.12
These  observations  suggested  that  this  monoclonal
may be a useful tool to monitor secretory activity in
human airways.
The aim of this study was to examine glycoconju-
gate secretion in human airways in vitro under basal
conditions and subsequent to methacholine stimula-
tion. In order to evaluate the role of the epithelium,
these experiments were performed in human bron-
chial ring preparations with an intact epithelium or in
bronchial  rings  in  which  the  epithelium  had  been
removed.
Materials and Methods
Tissues
Human lung tissues was obtained from patients (n =
34) who had undergone surgery for lung carcinoma.
Subsequent to the resection of lung, the subsegmental
bronchi were dissected free from parenchymal tissue
and washed with Tyrode’s solution.  The composition of
the Tyrode’s solution was (mM): NaCl 139.2, KCl 2.7,
CaCl2 1.8, MgCl2 0.49, NaHCO3 11.9, NaH 2PO4 0.4 and
glucose 5.5 pH 7.4. Bronchial tissues were cut as rings
(4–7mm,  internal  diameter  and  100–400mg,  wet
weight).  Bronchial  preparations  with  and  without
epithelium  were  examined.  The  epithelium  was
removed by gently rubbing the luminal surface of the
bronchial preparations with a moistened cotton swab.
Histological studies
Bronchial  rings  were  fixed  in  formalin  for  24h,
dehydrated,  emdedded  in  parafin  and  sections
(10m m) were cut and stained with haematoxylin and
eosin (2.5%) to evaluate general morphology.
The method for peroxidase staining was performed
as  previously  described,13 using  Dako  Kit  LSAB-2.
Briefly,  tissue  sections  were  deparaffinized  with
toluene,  rehydrated with ethanol and washed with
PBS. Endogenous peroxydases were eliminated with
H 2O2 (3%  for  5min). Tissue  sections  were  treated
with blocking serum (casein 0.25% in PBS; Dako) for
inhibition  of  cross  immunological  reactions.  The
tissues were incubated (10min) with anti-mucin 3D3
antibody  and  washed  with  PBS.  Thereafter,  the
sections  were  incubated  (10min)  with  peroxidase
coupled to streptavidine and peroxidase activity was
developed  using  diaminobenzidine/H 2O2.  Tissues
were counter-stained with Harris haematoxylin.
Functional studies
The preparations were set up in a microtitre plate (24
wells) containing Tyrode’s solution (1ml) and allowed
to equilibrate for 1h in a humidified incubator (37°C,
5% CO2/air). At the end of this equilibration period,
the  medium  was  exchanged  and  fresh  Tyrode’s
solution was added. The tissues were then maintained
for 1 hour (Period I: basal release). The medium was
collected  and  replaced  with  Tyrode’s  solution  or
Tyrode’s solution containing atropine (100m M). After
30min (treatment), the medium was exchanged with
Tyrode’s  solution  or  Tyrode’s  solution  containing
either  atropine  (100m M)  and/or  methacholine
(100m M). In some experiments, subsequent to the
incubation in Tyrode’s solution (30min) the bronchial
preparations  were  stimulated  with  either  LTD4
(10m M) or anti-IgE (dilution 1/1000). Following a 1h
exposure to these agents (Period II: post-treatment),
the  supernatants  were  again  collected. The  super-
natants  from Period I  and Period II  were stored at
–20°C.  Prior  to  determination  of  glycoconjugates
(ELISA), dithiotreitol (DTT) 0.1% in PBS solution was
added to these samples for 15min at 37°C14 to permit
solubilization  of  mucus  particulates  present  in  the
supernatants.
Glycoconjugate determination
The antigen and MAb 3D3 were a gift from Bayer plc
(UK) and details concerning purification and prepara-
tion have recently been published.11
The  glycoproteins  secreted  in  supernatants  of
human bronchial rings were detected by ELISA using
the MAb 3D3. Microplates (Nunc-Immunoplate Max-
isorp) were coated with a solution of MAb (dilution:
1/5000 in PBS) and incubated overnight at 4°C. The
plates were washed twice with 200 µl of PBS-Tween
20 (dilution: 1/1000) employing a microplate washer,
unbound  sites  were  blocked  with  (30mg/ml)  BSA
diluted in PBS for 1h at 37°C. The plates were washed
with  a  dilution  of  purified  human  3D3  antigen
standard in PBS–Tween-20 (1–500ng/50m l) and the
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distributed in the wells and incubated for 1 h at 37°C.
Following,  three  washes  with  Tris–Tween-20,  the
MAb 3D3 mixed with normal mouse serum and anti-
mouse immunoglobulin IgG conjugated with alkaline
phosphatase (1/500 in Tris–polyethylenglycol (PEG at
4%)  was  added  to  wells  and  incubated  for  1h  at
37°C.  The  plates  were  washed  twice  with  Tris–
Tween-20  and  developed  using  a  solution  of
p-nitrophenylphosphate (pNpp) diluted in 0.2M Tris
buffer pH > 8 to give a final concentration (1mg/ml)
substrate. The reaction was terminated (15–20min)
when  the  optical  densities  (OD)  correspond  to
maximal  concentration  from  3D3  antigen  standard
attained 0.8 OD units. Optical densities were meas-
ured  with  a Titertek-Multiskan  (Labsystems)  micro-
plate  reader  using  a  wavelength  of  405  nm.  The
amount of glycoconjugate released was interpolated
from  the  3D3  antigen  standard  curve.  A  standard
curve  with  dithiotreitol  was  carried  with  different
amount of 3D3 antigen (1–250ng/50m l), the dithio-
treitol (0.1%) was added to the maximal concentra-
tion of antigen and serial dilutions were subsequently
performed.  Since  the  monoclonal  antibody  3D3  is
directed specifically against the Leb antigen only the
supernatants of Leb individuals in which measurable
levels  of  glycoconjugate  were  observed,  are  pre-
sented in the results section. In lung samples from 11
of the 34 different patients examined (approximately
30%),  the  Leb antigen  was  not  detected. The  per-
centage of different lung samples in which the Leb
antigen was detected was similar to the population
estimate for Leb antigen carrying subjects.
Source of products
Plates (maxi-sorp Nunc), Tris (Prolabo), polyethylene
glycol 6000 (Merck), Kit LSAB-2 for immunolabelling
containing diaminobenzidine (Dako Laboratories). All
the  remaining  products;  methacholine,  atropine,
mouse  serum,  anti-mouse  immunoglobulin  coupled
with  alkaline  phosphatase,  bovine  serum  albumin,
dithiotreitol  (DTT),  Tween-20,  p-nitrophenylphos-
phate (pNpp) were from Sigma Chemical Co., USA.
The LTD4 was a gift from Dr P . J. Gardiner (Bayer plc).
The  sheep  antiserum  to  human  IgE  (anti-IgE)  was
obtained  from  Nordic  Immunological  Laboratories,
Tilberg, the Netherlands.
Calculation
The data are represented as (m g/g tissue) or (%   of
basal  level,  that  is,  Period  II/Period  I  3 100). All
results are means ± SEM and n indicates the number
of  lung  samples.  Statistical  analysis  was  performed
using Student’s t-test or Mann–Whitney rank sum test.
A  value  (P <  0.05)  was  taken  as  an  indication  of
significance.
Results
Histological data
Mechanical removal of the epithelium by rubbing the
luminal  surface  of  human  isolated  bronchial  ring
preparations led to the complete obliteration of the
epithelium while the basement membrane was left
intact (Fig. 1). In human bronchial ring preparations
after treatment with MAb 3D3, staining showed that
this  MAb  3D3  antibody  was  associated  with  two
specific tissue regions, namely, the epithelial layer and
submucosal glands (Fig. 2).
Functional data
The  DTT  did  not  alter  the  3D3  antigen  standard
curve  (Fig.  3.).  In  11  of  the  34  different  lung
samples studied in this assay (32%), the glycoconju-
gate  levels  were  below  the  threshhold  level  of
detection. The  mean  basal  secretion of  glycoconju-
gates in human airways in vitro was 100 ± 28m g/g
tissue (Period I; n = 23 different lung samples). The
amount of glycoconjugate measured in the medium,
derived from human isolated bronchial ring prepara-
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FIG.  1.  Top:  Morphological  aspects  of  human  bronchial
preparation  with  an  intact  epithelium. The  presence  of  a
pseudostratified  epithelium  with  goblet  cells  and  ciliated
cells was observed (magnification 3 100). Bottom: Human
bronchial  preparations  without  epithelium.  Tissues  were
stained with haematoxylin and eosin (magnification 3 50).tions,  did  not  change  under  control  conditions
during  the  course  of  the  experimental  procedure
(Period I; 128 ± 46m g/g tissue and Period II; 159 ±
48m g/g tissue; n = 13 paired lung samples). In the
supernatants  of  airway  preparations  with  an  intact
epithelium the amount of glycoconjugates detected
was 90 ± 38m g/g tissue (Period I; n = 12 different
lung samples) and removal of the epithelium did not
alter this basal glycoconjugate release (94 ± 60m g/g
tissue: Period I, n = 8 different lung samples). The
absence  of  the  epithelial  layer  was  confirmed  by
histological evaluation.
In human isolated bronchial ring preparations with
an  intact  epithelium  methacholine  (100m M)  pro-
duced a significant increase in the amount of glyco-
conjugate  detected  in  the  medium  (Fig.  4).  In
contrast,  no  significant  change  was  observed  in
human bronchial preparations stimulated with either
LTD4 (10m M; n = 3, 48 ± 24%) or anti-IgE (dilution
1/1000; n =  5, 76  ± 17%). The 10-fold increase  in
glycoconjugate release induced by methacholine was
attenuated  by  atropine  (100m M).  Results  derived
from  similar  experiments  performed  in  bronchial
rings  where  the  epithelium had  been removed are
presented  in  Fig.  5.  These  data  demonstrate  that
removal of the epithelium did not significantly alter
either the basal or stimulated levels of glycoconjugate
in the tissue medium.
Discussion
MAb 3D3, a marker of secretory glycoconjugates11,12
was  used  to  determine  glycoconjugate  release  in
human  airways  in  vitro.  Histochemical  analysis
revealed that the glycoconjugates which reacted with
MAb 3D3 were associated with both the epithelium
and the glandular mucus cells of the human bronchus.
Methacholine appeared to be the most effective agent
to stimulate glycoconjugate release in this model. In
addition,  the  amounts  of  glycoconjugates  detected
(basal  and stimulated levels)  as  measured with  the
MAb 3D3 were not dependent on the presence of the
H. Soss´ e-Alaoui et al.
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FIG. 2. Immunohistochemical labelling of human bronchus
with MAb 3D3. The MAb 3D3 labelled both the epithelium
including mucus goblet cells and mucus  cells of the sub-
mucosal glands (magnification 3 40).
FIG. 3. Effects of DTT on 3D3 antigen standard curve (ELISA).
Standard curve with (j ; n= 6) or without (d ; n= 3) DTT. The
DTT (0.1%) was added to the standard maximal concentra-
tion  of  3D3  antigen  and  serial  dilutions  were  performed.
Results are presented as glycoconjugate (ng/ml). Values are
means ± SEM and p indicates P<0.05 (Student’s t-test).
FIG. 4. The effects of muscarinic agents on glycoconjugate
release  from  human  bronchial  preparations  with  intact
epithelium. Unstimulated tissues (Ctrl; n = 7) and prepara-
tions  treated  with  either  atropine  (Atr,  100m M;  n =  4),
methacholine (MCh, 100m M; n = 7) or atropine and metha-
choline (Atr/MCh, 100m M; n = 4). Results are represented as
%  basal release. Values are means ± SEM and (n) indicates
number  of  different  lung  samples.  (p )  indicates  P <  0.05
(Mann–Whitney rank sum test).epithelium  since  removal  of  this  layer  did  not
significantly  alter  either  the  basal  or  methacholine
induced release.
Stahl  and  Ellis2 published  a  biochemical  study
showing  that  removal  of  the  epithelium  in  dog
airways permitted the detection of several glycopro-
teins thereby assigning the release of different sub-
stances to the epithelium or the mucosal glands of the
respiratory  tract  of  this  species.  Removal  of  the
epithelium  produced  a  significant  decrease  in  the
secretion of sulphated glycoproteins suggesting that
goblet cells in the epithelium were responsible for
these  constituents.  In  addition,  these  authors  also
showed  that  while  the  epithelial  layer  and  the
mucosal  glands  secrete  different  macromolecules,
they also  interacted in the  formation  of  the  larger
glycoconjugates which are released into the airway
lumen.
Previous reports in human airway tissues6,10,14 have
demonstrated that  there was little or no change in
basal  secretion under  control  conditions, however,
methacholine induced significant increases in secre-
tory  activity. The  results  (present  report)  confirm
these initial observations and are in agreement with
data derived from other species, such as the cat. In
contrast, in this model (present report) LTD4 and anti-
IgE  did  not  induce  glycoconjugate  release.  These
results  are  different  from  previous  reports  where
secretory  activity  was  assessed  using  radioactive
markers.  Marom  and  coworkers15 showed  a  small
increase in release from human airways in vitro (40%
above control levels) using either LTC4 or LTD4. These
data were also supported by the investigation of Coles
and coworkers16 who demonstrated a similar leuko-
triene-induced secretory release from human airways.
However, radioactive elements may be incorporated
into several cells and mark a variety of molecules,17
these differences in results may be explained in part
by  the  specificity  of  the  markers  employed  to
determine secretory activity.
However,  removal  of  the  epithelium  did not  sig-
nificantly  modify  either  the  basal  secretion or  that
induced by methacholine stimulation (present report)
when the MAb 3D3 was used to evaluate glycoconju-
gate release from human airways. Therefore species
differences  may  also  exist  since  Sasaki  and  co-
workers4 showed that in the respiratory tract of the
cat the epithelium modified the secretory activity of
the submucosal glands. The data from human airways
(present report) would also suggest that the metha-
choline is acting principally at the glandular level. The
lack of cholinergic response at the goblet cell level
may be due to the absence of neuronal inputs18 at the
surface  epithelium.  In  addition,  Mak  and  Barnes19
using  an  autoradiographic  technique  in  human  air-
ways demonstrated that  muscarinic receptors were
not detected in the epithelial layer, since no radiolabel
was  observed,  although  label  was  detected  in  the
region of the glands. Such results would suggest that
muscarinic  receptors  may  not  be  present  in  the
epithelium  in  human  airways.  However,  a  recent
publication has demonstrated that muscarinic recep-
tor  mRNA  is  detected  in  the  human  respiratory
epithelium.20 While the autoradiographic  technique
may not provide adequate sensitivity to detect mus-
carinic receptors, their location and function in the
epithelium has not been adequately evaluated.
While initial reports showed that epithelial cells in
culture  fail  to  secrete  mucin  and/or  mucin-like
glycoproteins,2 recent studies using human epithelial
cells in culture have demonstrated that a number of
substances including mucins could be detected after
several weeks in culture.12 While these investigators
demonstrated  that  epithelial  cells  in  culture  were
stained with the MAb 3D3, no indication as to the
function of these epithelial cells was examined. The
data  from  intact  human  airways  in  vitro (present
report) extend the work of Emery and coworkers11
and demonstrate that the MAb 3D3 may also be used
to detect basal and methacholine induced secretory
activity.  However,  the  functional  studies  (present
report) suggest that while the epithelial layer may fix
the MAb 3D3, there was little or no secretory activity
detected  by MAb 3D3  from  this  layer.  In  addition,
removal of the epithelium did not modulate either the
basal  or  stimulated  release  of  glycoconjugates  in
human airway preparations.
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FIG. 5. Glycoconjugate release from human bronchial pre-
parations  either  with  (j )  or  without  (h )  epithelium.  The
preparations were unstimulated (Ctrl) or stimulated (MCh,
100m M). Values are means ± SEM from 5–12 lung samples.
(p ) indicates P < 0.05 (Mann–Whitney rank sum test).In human airways, the MAb 3D3 may be used as a
marker of glycoconjugate release and this secretory
activity is principally associated with the submucosal
glandular level.
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